Search

Author/Creator Marín-Jiménez, I

1. DOP32 Long-term outcomes of enterocutaneous fistula complicating Crohn's Disease: The ECUFIT study from GETECCU. (27th May 2021)

Authors:
Rodríguez-Lago, I; García Pérez, C; Calafat, M; Soto, M P; Calvo, M; Sánchez Rodríguez, E; Caballol, B; Vela, M; Rivero, M; Muñoz, F; De Castro, L; Calvet, X; García-Alonso, F J; Utrilla Fornals, A; Ferreiro-Iglesias, R; González-Muñoza, C; Chaparro, M; Luis, B; Sicilia, B; Alfambra, E
Journal:
Journal of Crohn's and colitis
Issue:
Volume 15(2021)Supplement 1
Page Start:
S070
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. DOP40 Comorbidities and epidemiological risk factor but not immunosuppressive therapies increase the risk of COVID-19 in Inflammatory Bowel Disease (IBD): An ENEIDA-based, case-control study. (27th May 2021)

Authors:
Zabana Abdo, Y; Marín-Jiménez, I; Rodríguez-Lago, I; Vera, I; Martín, M D; Guerra, I; Gisbert, J P; Mesonero, F; Benítez, O; Taxonera, C; Ponferrada-Díaz, Á; Piqueras, M; Lucendo, A; Caballol, B; Mañosa, M; Martínez-Montiel, P; Bosca-Watts, M; Gordillo, J; Bujanda, L; Manceñido, N
Journal:
Journal of Crohn's and colitis
Issue:
Volume 15(2021)Supplement 1
Page Start:
S078
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Inflammatory Bowel Disease (IBD) and immunosuppression do not worsen the prognosis of COVID-19. Results from the ENEIDA Project of GETECCU. (27th May 2021)

Authors:
Zabana Abdo, Y; Marín-Jiménez, I; Rodríguez-Lago, I; Ramírez Esteso, F; Meijilde, S; Ramos, L; Gomollón, F; Muñoz, F; Suris, G; Ortiz de Zárate, J; Huguet, J M; Llaó, J; García-Sepulcre, M; Sierra, M; Durà, M; Estrecha, S; Fuentes Coronel, A; Hinojosa, E; Olivan, L; Iglesias, E
Journal:
Journal of Crohn's and colitis
Issue:
Volume 15(2021)Supplement 1
Page Start:
S553
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. P086 Sphk2 deletion is involved in structural abnormalities and Th17 response but does not aggravate colon immune dysregulation and intestinal permeability in a stress-induced colonic inflammation. (27th May 2021)

Authors:
Martin-Hernández, D; Robledo Montaña, J; López-Gutiérrez, I; González-Prieto, M; González Bris, Á; Ulecia-Morón, C; MacDowell, K; Tendilla-Beltrán, H; Moreno, B; Calleja-Rodríguez, N; Rodríguez-Mascarenhas, S; Caso, J R; García-Bueno, B; Marín-Jiménez, I; Leza, J C; Menchen Viso, L A
Journal:
Journal of Crohn's and colitis
Issue:
Volume 15(2021)Supplement 1
Page Start:
S186
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. P127 Anti-TNFs patterns of use in clinical practice in inflammatory bowel disease (VERNE study). (25th January 2019)

Authors:
Bastida, G; Marín-Jiménez, I; Forés, A; García-Planella, E; Argüelles-Arias, F; Sarasa, P; Tagarro, I; Fernández-Nistal, A; Montoto, C; Aguas, M; Santos-Fernández, J; Boscá, M; Ferreiro-Iglesias, R; Merino, O; Aldeguer, X; Cortés, X; Sicilia, B; Mesonero, F; Barreiro-de Acosta, M
Journal:
Journal of Crohn's and colitis
Issue:
Volume 13(2019)Supplement 1
Page Start:
S151
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. P309 Impact of co-morbidities on loss and lack of response to anti-TNFs in inflammatory bowel disease: VERNE study. (25th January 2019)

Authors:
Marín-Jiménez, I; Bastida, G; Forés, A; García-Planella, E; Argüelles-Arias, F; Sarasa, P; Tagarro, I; Fernández-Nistal, A; Montoto, C; Aguas, M; Santos-Fernández, J; Boscá, M; Ferreiro-Iglesias, R; Merino, O; Aldeguer, X; Cortés, X; Sicilia, B; Mesonero, F; Barreiro-de Acosta, M
Journal:
Journal of Crohn's and colitis
Issue:
Volume 13(2019)Supplement 1
Page Start:
S254
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. P436 Efficacy and safety of intravenous ustekinumab re-induction therapy in Crohn's disease patients with secondary loss of response to ustekinumab maintenance therapy: Week 16 results from the POWER trial. (30th January 2023)

Authors:
Schreiber, S W; Lee, S; van der Woude, C J; Marín-Jiménez, I; Wolf, D; Schnoy, E; Salzberg, B; Busse, C; Nazar, M; Langholff, W; Borghorst, S; Gasink, C; Baker, T; Godwin, B; Feagan, B
Journal:
Journal of Crohn's and colitis
Issue:
Volume 17(2023)Supplement 1
Page Start:
i564
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. P634 Ustekinumab and vedolizumab as first-line biological therapy for inflammatory bowel disease. A multicenter study based on the ENEIDA registry. (30th January 2023)

Authors:
Calafat Sard, M; Pascual, I; Nos, P; Barrio, J; Gutiérrez, A; Martín-Arranz, M D; Ricart, E; Gomollón, F; Sierra Ausín, M; Huguet, J M; Guardiola, J; Vera, I; Varela, P; Iglesias, E; Garcia-Planella, E; de Castro, L; García Sepulcre, M F; Sicilia, B; Fernández-Salazar, L; Calvet, X
Journal:
Journal of Crohn's and colitis
Issue:
Volume 17(2023)Supplement 1
Page Start:
i766
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗